CBS 2019
CBSMD教育中心
English

科学研究

科研文章

荐读文献

Efficacy of Ertugliflozin on Heart Failure–Related Events in Patients With Type 2 Diabetes Mellitus and Established Atherosclerotic Cardiovascular Disease Results of the VERTIS CV Trial Initial Invasive or Conservative Strategy for Stable Coronary Disease When and how to use SGLT2 inhibitors in patients with HFrEF or chronic kidney disease Risk of Mortality Following Catheter Ablation of Atrial Fibrillation Patient Selection and Clinical Outcomes in the STOPDAPT-2 Trial: An All-Comer Single-Center Registry During the Enrollment Period of the STOPDAPT-2 Randomized Controlled Trial Unexpectedly Low Natriuretic Peptide Levels in Patients With Heart Failure Dapagliflozin and Cardiovascular Outcomes in Type 2 Diabetes Heart Failure With Mid-Range (Borderline) Ejection Fraction: Clinical Implications and Future Directions Safety of six-month dual antiplatelet therapy after second-generation drug-eluting stent implantation: OPTIMA-C Randomised Clinical Trial and OCT Substudy The Management of Atrial Fibrillation in Heart Failure: An Expert Panel Consensus
|<<... 87 88 89 90 91 92 93 ...>>|

Clinical TrialDecember 8, 2020 Vol 142, Issue 23

JOURNAL：Circulation. Article Link

Efficacy of Ertugliflozin on Heart Failure–Related Events in Patients With Type 2 Diabetes Mellitus and Established Atherosclerotic Cardiovascular Disease Results of the VERTIS CV Trial

F Cosentino , CP Cannon , DZI Cherney et al. Keywords: ertugliflozin;T2DM; ASCVD, HF

Full Text PDF

>CBS CBS 2019

> CBS 2019

> CBS 2019 注册

> CBS 2019 会议日程

> CBS 2019 学术征集

> CBS 2019 热点

 CBSMD

> CBSMD 网站注册

> 教育中心

> 荐读文献

> Top 10 阅读文献

> 文献导读
CBS 2019 CBS 2019 主席团 教育中心 科研动态
Copyright ⓒ CBS MD Nanjing China. All rights reserved. 京ICP备16025898号-11
联系我们| Top